Posters

Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting

Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting

Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting

David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology

Irina M. Shapiro, Vihren N. Kolev, Christian M. Vidal, Mitchell Keegan1, Qunli Xu, Craig Menges, Joseph R. Testa and Jonathan A. Pachter
September 14, 2012
P1.14; International Mesothelioma Interest Group

Jonathan A. Pachter, Vihren N. Kolev, Alissa A. Neill, Quentin Wright, Mahesh V. Padval & Qunli Xu
November 09, 2012
405; 2012 EORTC/AACR Molecular Targets Meeting

Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Jennifer E. Ring, Mahesh V. Padval, Mitchell Keegan, and Jonathan A. Pachter
November 09, 2012
400; 2012 EORTC/AACR Molecular Targets Meeting

Jennifer E. Ring, Vihren N. Kolev, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Jonathan A. Pachter, and Qunli Xu
December 08, 2012
P6-11-07; 2012 San Antonio Breast Cancer Symposium

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Qunli Xu and Jonathan A. Pachter
December 08, 2012
P6-11-09; 2012 San Antonio Breast Cancer Symposium

Vihren N. Kolev, Quentin G. Wright, David T. Weaver, Jennifer E. Ring, Christian M. Vidal, Mahesh V. Padval, Jonathan A. Pachter and Qunli Xu
April 07, 2014
AACR 2014

Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Jennifer E. Ring, Christian M. Vidal, Irina M. Shapiro, David T. Weaver, Mahesh V. Padval and Jonathan A. Pachter
April 07, 2014
AACR 2014

Anthony F. Trombino, Mahesh V. Padval, Quentin F. Wright and Qunli Xu
April 07, 2014
AACR 2014

Paul Baas¹, Dean Fennell², Richard J. Gralla³, Hedy Kindler⁴, Lee M. Krug⁵, Anna K. Nowak⁶, Lawrence H. Schwartz⁷, Mitchell Keegan⁸, Joanna C. Horobin⁸
October 23, 2014
iMig, Cape Town October 2014

1. The Netherlands Cancer, Amsterdam NL; 2. University of Leicester, Leicester UK; 3. Albert Einstein College of Medicine, Bronx, NY USA; 4. University of Chicago, Chicago, IL USA; 5. Memorial Sloan-Kettering Cancer Center, New York, NY USA; 6. University of Western Australia, Perth, AU; 7. Columbia University College of Physicians and Surgeons, New York USA; 8. Verastem, Needham, MA USA

Qunli Xu¹, Winnie F. Tam¹, Christian M. Vidal¹, Vihren N. Kolev¹, Yuwaraj Kadariya2, Craig W. Menges², Joseph R. Testa², and Jonathan A. Pachter¹
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA

Vihren N. Kolev¹, Mahesh V. Padval¹, Quentin G.Wright¹, Jill Ricono², David T. Weaver1, Jonathan A. Pachter¹, and Qunli Xu¹
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Molecular Response, San Diego, CA

1Toshio Shimizu, MD, PhD, 2Hidemi Aida, PhD, 2Chiaki Hashii, 3Joanna Horobin, MB, ChB, 3Mitchell Keegan, PhD, 3Mahesh Padval, PhD, 3Anne Poli, 3Lindsey Wilson, 1Kazuhiko Nakagawa, MD, PhD

November 21, 2014
EORTC, Barcelona November 2014

1Phase 1 Clinical Trials Program, Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan; 2Japan Clinical Research Operations (JCRO), Tokyo, Japan; 3Verastem, Inc., Boston, MA, USA

Jonathan A. Pachter¹, Vihren N. Kolev¹, Laurel Schunselaar³, Irina M. Shapiro¹, Raphael Bueno², Paul Baas³, David T. Weaver¹ and Qunli Xu¹
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, Jonathan A. Pachter, PhD, Mahesh V. Padval, PhD, Qunli Xu, PhD, David T. Weaver, PhD

December 07, 2014
56th ASH Annual Meeting & Exposition

Verastem Inc., Boston, MA

Y Zhang, M Moschetta, D Huynh, YT Tai, Y Zhang, W Zhang, Y Mishima, JE. Ring, WF Tam, Q Xu, P Maiso, M Reagan, I Sahin, A Sacco, S Manier, Y Aljawai, S Glavey, NC Munshi, KC Anderson, J Pachter, AM. Roccaro, IM. Ghobrial Dana
December 07, 2014
56th ASH Annual Meeting & Exposition

Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA; Verastem Inc., Cambridge, MA

Mark B. Meads¹, Bin Fang2, Linda Mathews¹, Jennifer Gemmer¹, Liang Nong¹, Ismael Rosado – Lopez¹, Tuan Nguyen¹, Jennifer E. Ring⁷, William Matsui⁵, A. Robert MacLeod6 , Jonathan A. Pachter⁷, Lori A. Hazlehurst³, John M. Koomen^2,3, and Kenneth H. Shain^1,4
December 07, 2014
56th ASH Annual Meeting & Exposition

Departments of Chemical Biology and Molecular Medicine 1, Proteomics 2, Molecular Oncology 3, and Malignant Hematology 4 at Moffitt Cancer Center and Research Institute, Tampa, Florida 5, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 6 ISIS Pharmaceuticals, Carlsbad, California & 7 Verastem, Inc, Needham, Massachusetts

Barbara Muz¹, Maurizio Buggio¹, Feda Azab¹, Anthony F. Trombino², Mahesh Padval² and Abdel Kareem Azab¹
December 08, 2014
56th ASH Annual Meeting & Exposition

1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis MO, USA; 2 Verastem, Inc., Boston MA, USA

Vihren N. Kolev¹, Sean McDermott², Max Wicha², Jonathan A. Pachter¹, Qunli Xu1, David T. Weaver¹
December 14, 2014
San Antonio Breast Cancer Symposium

1Verastem, Inc., Boston, MA, 2University of Michigan Cancer Center, Ann Arbor, MI

Vihren N. Kolev, Qunli Xu, Mahesh Padval, Jonathan A. Pachter and David T. Weaver Verastem Inc., Boston, MA
April 20, 2015
AACR Annual Meeting 2015

Jonathan A. Pachter¹, Vihren N. Kolev¹, Laurel Schunselaar², Mahesh V. Padval¹, Irina M. Shapiro¹, Raphael Bueno³, Paul Baas2, Qunli Xu¹, and David T. Weaver¹
April 20, 2015
AACR Annual Meeting 2015

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

Udai Banerji¹, Dean Anthony Fennell², Hedy Lee Kindler³, Marjorie Glass Zauderer⁴, Mitchell Keegan⁵, Lou Vaickus⁵
September 09, 2015
2015 IASLC World Conference on Lung Cancer

VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor, Administered with a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects with Relapsed Malignant Mesothelioma

1 Royal Marsden Hospital, Sutton Surrey, UK; 2 University of Leicester, Leicester, UK; 3 University of Chicago, Chicago, IL, USA; 4 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 5 Verastem Inc., Boston, MA, USA

Hedy Lee Kindler¹, Dean Fennell², Paul Baas³, Marjorie Zauderer⁴, Anna K. Nowak⁵, Richard J. Gralla⁶, Takashi Nakano⁷, Marcelyne Joseney-Antoine⁸, Anne Poli⁸, Mitchell Keegan⁸, Lou Vaickus⁸
September 09, 2015
2015 World Conference on Lung Cancer

COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy

1 University of Chicago, Chicago, USA; 2 University of Leicester, Leicester, United Kingdom; 3 Netherlands Cancer Institute, Amsterdam, Netherlands; 4 Memorial Sloan-Kettering Cancer Center, NYC, USA; 5 University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Australia; 6 Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA; 7 Hyogo College of Medicine, Hyogo, Japan; 8 Verastem, Inc., Boston, USA

Jennifer E. Ring¹, Yajuan Li¹, Kam Sprott¹, Irina M. Shapiro¹, David DeNardo², Yan Wang¹, David T. Weaver¹, and Jonathan A. Pachter¹
November 05, 2015
SITC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

Vice President of Development, Verastem, Inc.

Hong Jiang¹,⁵, Samarth Hegde¹,⁵, Brett L. Knolhoff¹,⁵, Yu Zhu¹,⁵, John Herndon¹,⁵, Esther Leu⁴, William Hawkins³,⁶, Irina M. Shapiro⁷, David T. Weaver⁷, Jonathan A. Pachter⁷, Andrea Wang-Gillam¹,⁶, and David G. DeNardo¹,²,⁵,⁶
November 05, 2015
SITC 2015

1Department of Medicine, 2Department of Pathology and Immunology, 3Department of Surgery, 4Division of Biostatistics, 5ICCE Institute, 6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
7Verastem Inc., Needham, Massachusetts 02494, USA

November 06, 2015
EORTC 2015

Alan Serrels,¹,² Tom Lund,¹ Bryan Serrels,¹ Adam Byron,¹ Rhoanne C. McPherson,² Alexander von Kriegsheim,¹ Laura Gómez-Cuadrado,¹ Marta Canel,¹ Morwenna Muir,¹ Jennifer E. Ring,³ Eleni Maniati,⁴ Andrew H Sims,¹ Jonathan A. Pachter,³ Valerie G. Brunton,¹ Nick Gilbert,⁵ Stephen M. Anderton,² Robert J.B. Nibbs,⁶ and Margaret C. Frame¹

Hong Jiang¹,⁵, Samarth Hegde¹,⁵, Brett L. Knolhoff¹,⁵, Yu Zhu¹,⁵, John Herndon¹,⁵, Esther Leu⁴, William Hawkins³,⁶, Irina M. Shapiro⁷, David T. Weaver⁷, Jonathan A. Pachter⁷, Andrea Wang-Gillam¹,⁶, and David G. DeNardo¹,²,⁵,⁶

Jennifer E. Ring¹, Yajuan Li¹, Kam Sprott¹, Irina M. Shapiro¹, David DeNardo², Yan Wang¹, David T. Weaver¹, and Jonathan A. Pachter¹
November 06, 2015
EORTC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

Vihren N. Kolev, Yan Wang, Kam Sprott, Irina Shapiro, Jennifer Ring, Jonathan A. Pachter, David T. Weaver
November 06, 2015
EORTC 2015

Verastem Inc., Needham, Massachusetts 02494, USA

April 18, 2016
AACR 2016

Lisa M. Bean^1*, Florian J. Sulzmaier^1*, Isabelle Tancioni¹, Sean Uryu¹, Christine Jean¹, Xiao Lei Chen¹, Elizabeth G. Kleinschmidt¹, Kristen M. Anderson¹, Edward A. Cordasco¹, Joshua Axelrod¹, Vihren N. Kolev², Jonathan A. Pachter², Dwayne G. Stupack¹ and David D. Schlaepfer¹

April 18, 2016
AACR 2016

Yan Wang¹, Jennifer E. Ring¹, Kam Sprott¹, David DeNardo², David T. Weaver1 and Jonathan A. Pachter¹

Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to extend this therapeutic benefit to a greater proportion of patients. Combination of immunotherapy agents with tumor microenvironment modulators has the potential to overcome barriers that tumor cells develop to evade the immune system, and provide benefit to a greater proportion of patients. Focal Adhesion Kinase (FAK) and the family member PYK2 are potentially valuable targets due to their roles in regulating key cellular populations in the tumor microenvironment. In addition to targeting cancer stem cells, the FAK/PYK2 dual inhibitors, VS-6063 and VS- 4718, have been shown to inhibit monocyte-derived macrophages, reduce tumor-associated macrophages in xenograft models, and promote a CD8+ T cell-mediated anti-tumor response in squamous cell carcinoma models.

1 Verastem Inc., Boston, MA; 2 Washington University, St. Louis, MO

December 10, 2017

Xiangmeng Wang [1], [2] , Po Yee Mak [1], Mu Hong [1], Wenjing Tao [1], Jonathan Pachter [3], David Weaver [3], Bing Xu [4], Michael Andreeff [1], Bing Z Carter [1].
[1] Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;  [2] Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R.China;  [3] Verastem, Inc, Needham, MA;  [4] Department of Hematology, The first Affiliated Hospital of Xiamen University, Xiamen, P.R.China

Presenter: Xiangmeng Wang, Ph.D., MD Anderson Cancer Center
Abstract Number/Publication ID: 2653
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date and Time: Sunday, December 10, 2017 from 6:00-8:00 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Mitchell Keegan, VP Development – Verastem
October 23, 2014
iMig, Cape Town October 2014

Raphael Bueno¹, Ritu R Gill¹, Julianne Barlow¹, David M Jackman¹, Beow Y Yeap¹, David Weaver², Mahesh Padval², Rachel Sorensen², Mitchell Keegan²
October 23, 2014
iMig, Cape Town October 2014

1. Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA

Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014

December 08, 2014
56th ASH Annual Meeting & Exposition

Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Development, Verastem, Inc.

Jonathan Pachter
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Research, Verastem, Inc.

David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Scaglioni, Marilyn Li, Mitchell Keegan, Joanna C. Horobin, Timothy F. Burns
September 09, 2015
2015 World Conference on Lung Cancer

David Weaver
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Translational Research, Verastem, Inc.

Jonathan Pachter, VP/Head of Research, Verastem
March 10, 2016
Keystone Symposium on Stem Cells and Cancer

March 22, 2016
Annual Meeting on Women’s Cancer | SGO

Raphael Bueno, M.D.
May 03, 2016
The International Mesothelioma Interest Group (iMig)

Mini Symposium 10: Novel Targets – Entering in the Clinic (Track: Early Phase Clinical Trials)

Keystone Symposium on Cancer Pathophysiology

Lead Author: Bing Carter, Ph.D., Associate Professor, Department of Leukemia – Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Saturday, December 3, 2016, 5:30 – 7:30 pm PT

David G. DeNardo, PhD. Department of Medicine, Department of Path/Immunology
April 02, 2017
AACR 2017

June 26, 2017

E-Poster Presentation

Title: DYNAMO: The Clinical Activity of Duvelisib in Patients with Double-Refractory Small Lymphocytic Lymphoma in a Phase 2 Study
Abstract code: E1130
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Location: e-poster screens
Date and time: Friday, June 23, 2017 from 9:30 CET to Saturday, June 24, 2017 at 19:00 CET

Jonathan Pachter, Ph.D., Verastem
December 09, 2017

Title: The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model
Presenter: Jonathan Pachter, Ph.D., Verastem
Abstract Number/Publication ID: 1541
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
Date and Time: Saturday, December 9, 2017 from 5:30-7:30 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Alison J. Moskowitz MD, Raphael Koch MD, Neha Mehta-Shah MD, Patricia Myskowski MD, Meenal Kheterpal MD, Ahmet Dogan MD PhD, Theresa Davey MPAS, Natasha Galasso BA, Marzouk Evan BA, Monica Shah BA, Nivetha Ganesan BS, Lakeisha Lubin BS, Youn H. Kim MD, Michael Khodadoust MD PhD, Timothy Almazan MD, Julia Dai MD, Eric D. Jacobsen MD, David M. Weinstock MD, and Steven M. Horwitz MD
December 11, 2017
Presenter: Steven Horwitz, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number/Publication ID: 819
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T-Cell Lymphoma Clinical Studies; Monday, December 11, 2017 from 4:30-6:00 PM ET
Date and Time: Monday, December 11, 2017 at 5:00 PM ET
Location: Georgia World Congress Center, Building A, Level 4, Marcus Auditorium

Jonathan A. Pachter and David T. Weaver
January 26, 2018

Presenter: Jonathan A. Pachter and David T. Weaver
Poster: 33
Session: ASCO-SITC Clinical Immuno-Oncology Symposium
Date and Time: January 26, 2018
Location: San Francisco, California, USA

Carla Casulo, M.D., Assistant Professor, Wilmot Cancer Institute, University of Rochester
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 pm PT

Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt, Z Nagy, O Tournilhac, KE Abou-Nassar, M Crump, ED Jacobsen, S de Vos, P Santabarbara, W Shi, L Steelman, ND Wagner-Johnston
December 05, 2016

American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 5, 2016, 6:15 pm PT

June 16, 2017

Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma

88% of Patients had a Reduction in the Size of Target Lymph Nodes

Duvelisib Remains Well-Tolerated in Long-Term Follow Up

June 26, 2017

Oral Presentation

Title: DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Follicular Lymphoma
Abstract code: S777
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Session title: Follicular lymphoma – Clinical
Location: Hall C
Date and time: Sunday, June 25, 2017, 8:45 – 9:00 CET

December 10, 2017

Title: Results from the Phase 3 DUO™ Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Presenter: Ian Flinn, M.D., Ph.D., Sarah Cannon Research Institute
Abstract Number/Publication ID: 493
Session: 642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments; Sunday, December 10, 2017 from 4:30-6:00 PM ET
Date and Time: Sunday, December 10, 2017 at 4:30 PM ET
Location: Georgia World Congress Center, Building B, Level 5, Murphy BR 3-4